SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras antibody candidate for menopausal hot flashes, and its Phase 1/2 data presentation at a menopause conference; traders are looking for added evidence on efficacy, durability and safety after encouraging Phase 2 topline results. Bulls see the data as a potential validation of the companys internal pipeline, while skeptics question whether the presentation adds enough beyond known results and warn that expectations and recent volatility may set up a sell-the-news reaction.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

Renewed, unconfirmed takeover chatter around a possible offer from an unidentified West Coast technology company is dominating discussion, with traders speculating about buyers such as Meta while others caution that no bid has been confirmed. Upcoming earnings and concerns about transaction margins are also in focus, but the takeover speculation is driving much of the debate.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs choppy trading is drawing attention amid rotation between small caps and large-cap tech, with traders debating whether small caps relative resilience signals a broader recovery or a temporary bounce. Speculation about a U.S.Iran deal and swings in oil prices have added volatility, but the reported diplomatic progress is disputed and traders remain wary of weak breadth and technical resistance.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is drawing attention amid a steep, prolonged selloff, with traders citing weakness across Chinese EV stocks, concerns about demand, profitability and analyst downgrades. Bulls counter that delivery growth, European expansion and AI-chip and robotics initiatives could support the business, while frustrated holders question whether those developments can improve shareholder returns.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Keytruda showed a 42% reduction in recurrence or death risk, but shares sold off as traders judged the outcome against high expectations after a major run-up. The community is split between viewing the data as strong validation of the cancer-vaccine platform and questioning whether the benefit, individualized manufacturing, and commercialization prospects justify the valuation.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillars sharp pullback and upcoming earnings report are driving debate, with traders questioning whether strong backlog and data-center power demand can justify elevated expectations or whether the selloff reflects concerns about slowing AI infrastructure spending. Some see the stock as oversold and are buying the dip, while others expect further weakness if guidance disappoints.

Crown Castle, Inc. engages in the business of owning, operating, and leasing shared communications infrastructure. It operates through the following segments: Towers, Fiber, and Other. The Towers segment focuses on providing coverage and capacity for wireless carrier network deployments. The Fiber segment includes communications infrastructure offerings of small cells and fiber solutions. The Other segment is involved in corporate assets such as cash and cash equivalents. The company was founded by Ted B. Miller Jr. and Edward C. Hutcheson Jr. in 1994 and is headquartered in Houston, TX.

Crown Castle Inc

Crown Castle International Corp

Reports that SpaceX is in talks to access U.S. cell sites, including Crown Castles towers, have driven the rally as traders weigh the prospect of a new source of leasing demand. No agreement is confirmed, and the community is divided over whether the potential business is realistic and how it could affect tower owners and wireless carriers.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charters steep selloff is drawing attention amid concerns about broadband subscriber losses, competition and its heavy debt burden. Bears see a deteriorating cable business, while bulls argue the valuation is too low given cash flow, Spectrum Mobile growth and the Cox deal; possible SpaceX ties remain speculation.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Novartis/Aviditys Phase 3 failure in DM1 has prompted a sharp read-through debate around Sareptas SRP-1003 program: some traders see a weakened competitor, while others worry the result questions whether DMPK knockdown can translate into functional benefit. The community is looking to Sareptas own DM1 and FSHD data to clarify the risk, with optimism that its different delivery approach may produce stronger results offset by uncertainty about clinical impact.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas expected Q4 2026 Phase 3 topline results for HLP003, its investigational add-on treatment for major depressive disorder. Traders are split between optimism that the readout could validate the program and concerns about trial uncertainty, potential dilution, and volatility around the binary catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HeartFlow's CEO Sells 38,900 Shares for $1.8 Million After the Stock Hit a 52-Week High

Key PointsThe transaction involved 38,900 shares valued at ~$1.8 million based on a weighted average price of $46.78 per share...

HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High

Key PointsThe sale of 33,416 shares generated a total value of approximately $1.7 million based on a weighted average execution price of $49.85...

HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?

Key PointsThe executive sold 9,219 shares at $41.23 per share on August 17, 2026, generating ~$380,100...

Why Heartflow Stock Soared Today

Key PointsHeartflow's AI-powered platform could save countless lives...

HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance

HeartFlow shares are surging Friday after it reported better-than-expected Q2 adjusted EPS results and raised its full-year outlook.read more...

Heartflow, Eton Pharmaceuticals, Nu Holdings And Other Big Stocks Moving Higher On Friday

U.S. stocks up, Dow Jones 0.1% higher. HeartFlow (HTFL) shares rise 26.5% on better-than-expected earnings. Other big gains include ETON, VALN, IMXI.read more...

HeartFlow Q2 2026 Earnings Call Transcript

HeartFlow (NASDAQ:HTFL) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This transcript is brought to you by Benzinga APIs. For real-time access toread more...

HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates

HeartFlow (HTFL) delivered earnings and revenue surprises of +50.00% and +12.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates

Stereotaxis (STXS) delivered earnings and revenue surprises of -66.67% and -19.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Doximity (DOCS) Q1 Earnings Lag Estimates

Doximity (DOCS) delivered earnings and revenue surprises of -3.33% and +3.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

HeartFlow, Inc. operates as a cardiovascular company which engages in diagnosing coronary artery diseases. The firm provides a patient-specific analysis of coronary blood flow utilizing coronary CT scans and proprietary computer algorithms based on computational fluid dynamics. The company was founded by Charles A. Taylor, Nathan M. Wilson, and Christopher K. Zarins in July 2007 and is headquartered in Mountain View, CA.

Heartflow Inc

EXCLUSIVE: Aclarion CEO Looks To Bigger AI MedTech’s Playbook To Reverse Fortunes 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>CEO Brent Ness outlined a 2026 execution plan focused on reimbursement, evidence, and adoption.</li><li>Monetization is underway through UK coverage, cash-pay usage, and paid trials.</li><li>Scanner expansion is seen as a key lever to broaden market reach.</li></ul>Aclarion Inc.’s stock has plunged nearly 98% over the past year, putting the spotlight back on the artificial intelligence-driven medical imaging company almost four years after it went public. Despite the steep decline, Aclarion is now attempting to follow a path similar to HeartFlow,&nbsp;an AI medtech firm focused on cardiac imaging, that went public just months ago with significantly higher quarterly revenue and greater investor visibility.In an exclusive interview with Stocktwits, CEO Brent Ness said Aclarion is already generating revenue. In this interview, edited for clarity, Ness explained how the Broomfield, Colorado-based company is working to regain investor confidence after a prolonged period of decline.<h2 class="st-heading-2">HeartFlow's Playbook Offers Guidance For Aclarion</h2>Ness compared Aclarion’s strategy to that of advanced imaging companies such as HeartFlow, noting that the “raw material data” comes from imaging centers, is processed in the cloud, and is delivered to physicians in a clinically meaningful report.Under this structure, imaging centers generate raw data that is processed through Aclarion’s platform and translated into clinically meaningful reports for physicians. Ness said customer acquisition and technology development are expensive, but delivering a cloud-to-customer scan has a “nice margin profile.”He said investors should look at HeartFlow “as a proxy business” when thinking about Aclarion’s economic profile. HeartFlow’s platform uses AI to generate personalized three-dimensional models of the heart, helping make coronary artery disease more screenable, diagnosable and manageable.Aclarion went public in April 2022, while HeartFlow made its market debut in August 2025. Over the past six months, HTFL has shed about 1.3% to keep its market capitalization at $2.45 billion, while ACON has slumped by nearly 60%, with its valuation hovering just above $3 million.&nbsp;HeartFlow’s quarterly revenue has increased from $26.8 million in the first quarter of 2024 to $46.3 million in the third quarter of 2025, while adjusted losses narrowed slightly, from $15.6 million to $14.8 million over the same period.&nbsp;Aclarion had approximately $21 million in cash at the beginning of January, giving the company a funding runway through 2028.<img src="https://news.stocktwits-cdn.com/Heart_Flow_Revenue_and_EBITDA_jpg_728fe48fd3.webp" alt="HeartFlow_Revenue_and_EBITDA.jpg"><h2 class="st-heading-2">A Big Market With Room To Scale</h2>Ness said Aclarion’s opportunity spans a large patient population, noting that approximately 266 million people worldwide live with chronic low back pain. He said the company’s addressable market spans multiple layers of care, including spinal fusion surgeries, non-fusion procedures, and pain management, collectively increasing the potential number of scans over time.According to a MarketsandMarkets&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketsandmarkets.com/PressReleases/ai-in-medical-imaging.asp">report</a>, the global AI in medical imaging market is projected to reach $4.54 billion by 2029, up from $1.65 billion in 2024, reflecting a 22.4% compound annual growth rate. The report said growth is driven by the rising adoption of AI software that improves diagnostic accuracy, streamlines workflows, and helps providers manage increasing imaging volumes.On potential near-term catalysts, Ness said the company is focused on reimbursement progress and expanding access. “We’re currently in the market only with Siemens scanners. If you see Philips scanners, Canon scanners, GE scanners coming on board, then that will increase the penetrable market size significantly.”<h2 class="st-heading-2">Early Monetization Gains Ground</h2>Ness said Aclarion is generating revenue from multiple sources, including reimbursed Nociscan scans in the UK, cash-pay usage, and paid clinical trials that compensate the company for use of its technology.He said the UK, particularly London, has played a key role because insurance coverage reduces financial friction for physicians and patients, thereby supporting higher utilization and growth in scan volume.Ness said clinical trials are also generating revenue, with some studies paying Aclarion to use Nociscan to evaluate spine treatments and biologics. He said this allows evidence generation to function as an income stream rather than a pure cost center, helping offset operating expenses and reducing reliance on capital markets during key development milestones.<h2 class="st-heading-2">Aclarion Clarity Trial And Reimbursement Pathway</h2>Ness said Aclarion’s national randomized Clarity trial is central to its U.S. reimbursement strategy. The trial is designed to enroll up to 300 patients, with physicians blinded or unblinded to Nociscan results. It will measure outcomes at 3, 6, and 12 months post-surgery, with additional follow-up at 24 months.Since it is a post-market study and not an FDA approval trial, he said the study includes an early-stop design, meaning enrollment could be halted if outcome separation becomes statistically significant, potentially accelerating discussions with insurers.Ness said that a 2025 paper by an independent PhD healthcare economist found Nociscan reduced costs by about $1,700 per patient, strengthening the case for payer adoption. He added that nearly $2.2 billion is spent each year in the U.S. on fusion revision surgeries, and said reducing that figure is a significant opportunity for payers.<h2 class="st-heading-2">ACON vs HTFL: Which Stock Is Getting Higher Retail Interest?</h2>On Stocktwits, Aclarion’s retail sentiment was ‘bearish’ amid ‘extremely low’ message volume, a sharp shift from ‘extremely bullish’ sentiment a year ago. HeartFlow’s sentiment was also ‘bearish’ with ‘normal’ message volume, down from ‘neutral’ levels last year.<figure class="image"><img src="https://news.stocktwits-cdn.com/acon_ss_png_3176ea0056.webp" alt="acon ss.png" width="967" height="140"><figcaption>ACON sentiment and message volume as of February 4 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/htfl_ss_png_d3f3abe807.webp" alt="htfl ss.png" width="966" height="141"><figcaption>HTFL sentiment and message volume as of February 4 | Source: Stocktwits</figcaption></figure>One user said they were accumulating Aclarion shares and watching closely for a pickup in trading volume, adding that “a fast double is very possible.”<stembedurl>https://stocktwits.com/KuruHabesha/message/643772716</stembedurl>Another Stocktwits user said HeartFlow’s momentum would likely persist only if the company continues to show consistency quarter to quarter, adding that operational execution needs to tighten meaningfully and that sustained improvement could help validate the long-term thesis.<stembedurl>https://stocktwits.com/MarketSignalMatrix/message/640221754</stembedurl>Up until the end of January, HTFL notched a more than 15% jump in watchers on Stocktwits over a three-month period, while ACON saw a merely 2.7% rise in followers, indicating stronger growth in retail investor interest for Heartflow. Message volume for HTFL doubled over the same period, while ACON witnessed a 25% drop.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aclarion logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

CEO Brent Ness noted a broad global market, with approximately 266 million people affected by chronic low back pain.

Aclarion CEO Bets On Bigger AI MedTech’s Playbook To Revive Sagging Stock

Aclarion Inc

Heartflow, Inc.

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$56.71
Prev Close	$55.43
Open	$55.27
Dividend Yield	0.00%
50-Day Moving Average	$49.38
Beta	1.87
Avg. Volume	1.97M
PE Ratio	-40.59

52-Week High	$57.74
52-Week Low	$20.13
Market Capitalization	$4.93B
EPS (Annual)	-$1.37
Price to Book	17.58
Revenue Per Employee	$208,818.51

Feed

News

Sentiment

Earnings

Fundamentals

Info

HTFL Fundamentals